Literature DB >> 3011242

Conditioned tumorigenicity of activated oncogenes.

G Klein, E Klein.   

Abstract

Virally transduced oncogenes (v-onc) have a restricted target cell spectrum. They transform only a small part of the cell types in which they are expressed. Temperature-sensitive (ts) mutant studies have shown that some of them may act by blocking specific steps of maturation. If the cell can bypass the block, e.g., by a temporary switch off of the temperature-sensitive transforming protein, reexpression of the oncogene product at the permissive temperature may be unable to restore the transformed phenotype. Consideration of these facts, together with evidence concerning the reversion of the transformed phenotype and the suppression of tumorigenicity in hybrids derived from the fusion of normal and malignant cells, leads to the concept of "conditioned tumorigenicity." It states that the transforming and/or tumorigenic effect of a given oncogene, activated by structural or by regulatory changes, is restricted to specific and often quite narrow differentiation or maturation windows within each susceptible lineage. A similar restriction seems to apply to oncogenes activated by chromosomal translocation. The regular juxtaposition of the c-myc gene to one of the three immunoglobulin loci in Burkitt's lymphoma, mouse plasmacytoma, and rat immunocytoma is a case in point. The myc-carrying chromosome can break at many different places, within, upstream, or downstream of the gene, but not within its coding exons. This suggests that the break occurs at random and the myc protein plays an essential role in the selective, i.e., tumorigenic process. If so, other oncogenes should be equally transposable to the "Ig hot spots" during the long series of cell divisions in the preneoplastic target cell population that characterizes the prehistory of both BL and MPC. In other human B-cell leukemias and lymphomas, other (e.g., 11;14 and 14;18) translocations have been found, confirming that this can actually occur, but only in histologically different neoplasms. The exclusive involvement of myc in BL and MPC must be relatable to the specific functional features of the precursor cells and to the normal role of the myc protein. Recent evidence indicates that the myc gene is regularly turned off before or at the time when the cell enters a pathway that is programmed to lead it towards a resting Go state. Clonally expanded B-cells are believed to turn into resting memory cells upon waning of the antigenic stimulus. The normal, nontranslocated myc allele is regularly switched off in both BL and MPC, indicating that the cell has already obeyed a program involving the down-regulation of myc.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3011242

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

1.  Drastically increased expression of MYC and FOS protooncogenes during in vitro differentiation of chronic lymphocytic leukemia cells.

Authors:  L G Larsson; H E Gray; T Tötterman; U Pettersson; K Nilsson
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

2.  Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.

Authors:  M G Masucci; S Torsteindottir; J Colombani; C Brautbar; E Klein; G Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1987-07       Impact factor: 11.205

Review 3.  The emerging complexity of gene fusions in cancer.

Authors:  Fredrik Mertens; Bertil Johansson; Thoas Fioretos; Felix Mitelman
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

4.  Epstein-Barr virus growth-transformed cells are converted to malignancy following transfection of a 1.3-kb CATR1 antisense construct independent of a change in the level of c-myc expression followed by a 8;14 chromosomal translocation.

Authors:  D Li; X L Sun; B Casto; J Fang; K Theil; R Glaser; G Milo
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

5.  In situ hybridization localizes the human putative oncogene GLI to chromosome subbands 12q13.3-14.1.

Authors:  K Arheden; M Rønne; N Mandahl; S Heim; K W Kinzler; B Vogelstein; F Mitelman
Journal:  Hum Genet       Date:  1989-04       Impact factor: 4.132

6.  Carcinogen-induced trans activation of gene expression.

Authors:  T Kleinberger; Y B Flint; M Blank; S Etkin; S Lavi
Journal:  Mol Cell Biol       Date:  1988-03       Impact factor: 4.272

7.  Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma.

Authors:  Zhongqiu Xie; Mihaela Babiceanu; Shailesh Kumar; Yuemeng Jia; Fujun Qin; Frederic G Barr; Hui Li
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

8.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Authors:  R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

Review 9.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

10.  Oncogenetics. A new emerging field of cancer.

Authors:  R S Verma
Journal:  Mol Gen Genet       Date:  1986-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.